EMILIE FUGATE: Open Payments
NPI 1215505144 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$972 in 21 payments from 6 companies in 2025. Trend: 2023 $947 · 2024 $927 · 2025 $972
Food & beverage: $972
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $491 |
| Astellas Pharma US Inc | 4 | $177 |
| Lilly USA, LLC | 7 | $154 |
| MERZ NORTH AMERICA, INC. | 1 | $113 |
| Galderma Laboratories, L.P. | 1 | $18 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $18 |
Products named: Wegovy, Veozah, Xeomin, ZEPBOUND, MOUNJARO, Quviviq.
Industry payments across FL — which companies pay providers there.
